Evidence map›Paper›PMID 40948985›Full record

ReviewThe EPMA journal2025

The 3PM transformation potential of minimal residual disease in solid tumor management: a bibliometric analysis and review.

Yining Chen, Xin Li, Suya Zhao, Yuchong Zhang, Haixu Wang, Fangjian Na, Qi Guan, Zhi Li, Heming Li, Mingfang Zhao

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The EPMA journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yining ChenDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, 110001 China.ORCID 0009-0008-0759-3378
Xin LiDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, 110001 China.
Suya ZhaoDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, 110001 China.
Yuchong ZhangDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, 110001 China.
Haixu WangDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, 110001 China.
Fangjian NaNetwork Information Center, China Medical University, Shenyang, 110000 China.
Qi GuanDepartment of Medical Oncology, The Fourth People's Hospital of Shenyang, Shenyang, 110001 China.
Zhi LiDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, 110001 China.
Heming LiDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, 110001 China.ORCID 0000-0002-5702-0147
Mingfang ZhaoDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, 110001 China.ORCID 0000-0003-0183-144X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over the past two decades, significant progress has been made in the study of minimal residual disease (MRD) in patients with solid tumors. Increasing evidence supports that monitoring and quantifying MRD can provide prognostic insights and enable personalized treatment strategies for patients who achieve complete remission. Although MRD is gradually being integrated into the clinical management of solid tumors, several challenges remain unresolved. This review combines bibliometric analysis with advances in cutting-edge technologies to examine the evolving landscape of MRD, emphasizing its alignment with the predictive, preventive, and personalized medicine (PPPM/3PM) paradigm. By synthesizing research trends, key challenges, and innovative approaches, we highlight the predictive value of MRD for relapse risk, its preventive role in early intervention, and its potential to guide real-time personalized therapies. We advocate for the standardization and integration of MRD monitoring into routine clinical oncology practice, reinforced by expert recommendations grounded in 3PM principles. Supplementary Information: The online version contains supplementary material available at 10.1007/s13167-025-00413-8.

Indexed as

Dynamic surveillanceEarly identification of relapse riskExpert recommendationsLiquid biopsyMinimal residual diseasePredictive preventive personalized medicine (PPPM / 3PM)Real-time personalized therapy guided by molecular signaturesRisk stratificationSolid tumorsTherapeutic resistanceTimely interventionTumor microenvironmental factors

Identifiers

PMID40948985
PMCPMC12423022

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.